TriSalus Life Sciences: Strategic Developments and Revenue Growth Drive Buy Rating

JonesTrading analyst Justin Walsh has reiterated their bullish stance on TLSI stock, giving a Buy rating today.

Justin Walsh’s rating is based on several strategic developments at TriSalus Life Sciences. The company has shifted its focus towards the commercialization of TriNav, which has shown promising revenue growth, with a 42% year-over-year increase in the first quarter of 2025. Despite the delay in achieving cash flow positivity, now expected in the first half of 2026, the company has maintained its revenue growth guidance of over 50% for the fiscal year 2025.
Additionally, TriSalus is actively seeking partnerships for the development of nelitolimod, which could lead to a steady stream of royalties. The anticipated launch of TriNav Flex, along with the reduction in R&D expenses following the completion of nelitolimod clinical trials, positions the company for future financial milestones. These strategic moves, coupled with the expectation of risk-adjusted royalties from nelitolimod sales, underpin the Buy rating and the $11 price target.

Walsh covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences, Actinium Pharmaceuticals, and Serina Therapeutics. According to TipRanks, Walsh has an average return of -6.5% and a 25.42% success rate on recommended stocks.

In another report released today, Lake Street also reiterated a Buy rating on the stock with a $10.00 price target.